New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:25 EDTABBV, ABBV, AET, AET, AMGN, AMGN, ESRX, ESRX, HSP, HSP, MNTA, MNTA, PFE, PFEFTC to hold a workshop
The Biologics Workshop explores competition issues involving biologic medicines and follow-on biologics with a focus on the potential impact of state regulations affecting competition. Companies participating include AbbVie, Aetna, Amgen, Express Scripts, Hospira, Momenta Pharmaceuticals and Pfizer at the FTC Washington, D.C. offices on February 4 at 8:30 am. Webcast Link
News For ABBV;AET;AMGN;ESRX;HSP;MNTA;PFE From The Last 14 Days
Check below for free stories on ABBV;AET;AMGN;ESRX;HSP;MNTA;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 21, 2014
06:43 EDTABBVGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
06:10 EDTABBVStocks with implied volatility movement; ABBV JOY
Subscribe for More Information
July 18, 2014
18:04 EDTABBVAbbVie purchase of Shire worth the premium, Barron's reports
Subscribe for More Information
16:47 EDTABBVMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
13:46 EDTABBVAbbVie price target raised to $85 from $71 at Jefferies
Subscribe for More Information
10:48 EDTHSPHigh option volume stocks
Subscribe for More Information
10:34 EDTABBVShire downgraded to Neutral from Overweight at Piper Jaffray
Shire (SHPG) is being acquired by AbbVie (ABBV).
10:30 EDTABBVAbbVie says can't back out of Shire deal based on tax law change, Bloomberg says
Subscribe for More Information
09:29 EDTABBVAbbVie, Shire says merger should help in enhanced buyback and dividend programs
Subscribe for More Information
05:17 EDTABBVAbbVie, Shire agree on merger worth GBP32B pounds
The boards of AbbVie (ABBV) and Shire (SHPG) announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie. Under the terms of the Merger, Shire shareholders will be entitled to receive per share GBP 24.44 in cash and 0.8960 new AbbVie shares. Immediately following the transaction, Shire shareholders are expected to hold new AbbVie Shares representing approximately 25% of the issued share capital of new AbbVie. AbbVie expects the transaction to be accretive to adjusted earnings per share in the first year following completion, growing to above $1.00 per share by 2020, with "material ongoing financial and operating benefits." The AbbVie board also expects the transaction to reduce New AbbVie's effective tax rate to approximately 13% by 2016. The Shire board said it "considers the terms of the Transaction to be fair and reasonable." In order to undertake the transaction, AbbVie has formed a new company, New AbbVie, which is incorporated in Jersey, Shire's current place of incorporation. Following completion of the Transaction, New AbbVie will become the holding company of the Shire Group and the AbbVie Group. It is intended that the New AbbVie Shares will be listed on the New York Stock Exchange.
05:12 EDTABBVAbbVie to acquire Shire for 52.48 pounds per share in cash, stock
Subscribe for More Information
July 17, 2014
16:10 EDTAMGNAmgen announces positive Phase 3 results for AMG 416
Subscribe for More Information
12:56 EDTABBVAbbVie set to announce GBP 31B deal to buy Shire, FT says
Subscribe for More Information
12:54 EDTABBVAbbVie set to announce GBP 31B deal to buy Shire, FT says
Subscribe for More Information
08:08 EDTPFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
05:53 EDTABBVStocks with implied volatility movement; HLF ABBV
Stocks with implied volatility movement; Herbalife (HLF) 52, AbbVie (ABBV) 30 according to iVolatility.
July 16, 2014
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
07:59 EDTPFE, ABBVTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use